# US 2016/0256550 A1 · Functional, cross-linked nanostructures for tandem optical imaging and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256550 A1
- Document ID: US20160256550A1
- Status: Published application
- Kind: A1
- Application number: 15/054,739
- Filed: 2016-02-26
- Published: 2016-09-08
- Earliest claimed: 2010-05-14
- Assignees: Mallinckrodt Inc.; Washington University; The Texas A&M University System
- Applicants: Mallinckrodt LLC
- Inventors: William L. Neumann; Richard B. Dorshow; John N. Freskos; Karen L. Wooley; Nam S. Lee; Yun Lin; Guorong Sun
- Web page: https://patentgrep.com/patent/US20160256550A1

## CPC

- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5192: {Processes}
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/351: not condensed with another ring
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6911: {the form being a liposome}
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0082: {micelle, e.g. phospholipidic micelle and polymeric micelle}
- A61K 49/0093: {Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle}
- A61M 5/007: {for contrast media}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.

## Claims

### Claim 1

A composition comprising:
an optical agent comprising cross linked block copolymers, wherein each of the block copolymers comprises a hydrophilic block and a hydrophobic block; wherein the hydrophilic block is a poly(acrylic acid) polymer block which has a number of monomers selected from the range of 10 to 250, and wherein the hydrophobic block is a polystyrene polymer block which has a number of monomers selected from the range of 40 to 100; and
linking groups covalently cross linking at least a portion of the hydrophilic blocks of the block copolymers, wherein at least a portion of the linking groups comprise one or more photoactive moieties; and
a therapeutic agent;
wherein the optical agent forms a supramolecular structure in aqueous solution, the supramolecular structure having an interior hydrophobic core and a covalently cross linked hydrophilic shell, wherein the interior hydrophobic core comprises the hydrophobic blocks of the block copolymers, and the covalently cross linked hydrophilic shell comprises the hydrophilic blocks of the block copolymers, and wherein the therapeutic agent is at least partially encapsulated by the supramolecular structure and the therapeutic agent is non-covalently associated with the hydrophobic core.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the supramolecular structure comprises a shell-cross linked micelle, a shell-cross linked spherical nanoparticle or a shell-cross linked rod-shaped nanostructure.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the supramolecular structure is spherical, cylindrical, discoidal, toroidal, vesicular or multi-compartment.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the optical agent is a shell-cross linked micelle having a cross sectional dimension selected from a range of 5 nanometers to 500 nanometers.

### Claim 5 (depends on 1)

The composition of claim 1 wherein said optical agent has a cross linking density of 5% to 35% and the mole ratio of the linking groups to monomers of the hydrophilic blocks is selected over a range of 1:100 to 99:100.

### Claim 6 (depends on 1)

The composition of claim 1 further comprising one or more targeting moieties.

### Claim 7 (depends on 6)

The composition of claim 6, wherein a targeting moiety is bonded to the hydrophilic blocks of at least a portion of the block copolymers.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the targeting moiety is a peptide, a protein, an oligonucleotide, an antibody, a carbohydrate, a hormone, a lipid or a drug.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the targeting moiety comprises a ST receptor binding agent, a bombesin receptor binding agent, a leukemia peptide, and a folate receptor binding agent.

### Claim 10 (depends on 1)

A method comprising administering a composition of claim 1 to a mammal, wherein the composition is an optical agent, the method comprising:
administering to a mammal an effective amount of the composition of claim 1, wherein the one or more photoactive moieties comprise one or more chromophores and/or fluorophores, wherein the therapeutic agent is a Taxol, an isolated polypeptide, comprising the amino acid sequence of SEQ ID NO: 1, paclitaxel or doxorubicin that is released from the supramolecular structure;
exposing the optical agent administered to the mammal to electromagnetic radiation; and
detecting electromagnetic radiation transmitted, scattered or emitted by the optical agent.

### Claim 11 (depends on 10)

The method of claim 10 wherein the optical agent is exposed to electromagnetic radiation having wavelengths selected over a range of 400 nanometers to 1300 nanometers.

### Claim 12 (depends on 1)

The composition of claim 1 wherein the procedure further comprises exciting luminescence from the optical agent.

### Claim 13 (depends on 1)

The composition of claim 1 wherein the procedure comprises a method of imaging a tumor of the mammal, wherein the administering provides the optical agent to the tumor.

### Claim 14

A shell-cross linked nanostructure comprising:
cross linked block copolymers, wherein each of the block copolymers comprises a hydrophilic block and a hydrophobic block; wherein the hydrophilic block is a poly(acrylic acid) polymer block which has a number of monomers selected from the range of 10 to 250, and wherein the hydrophobic block is a polystyrene polymer block which has a number of monomers selected from the range of 40 to 100; wherein the hydrophilic block is directly or indirectly bonded to the hydrophobic block; and
pyrazine-containing linking groups covalently cross linking at least a portion of the poly(acrylic acid) polymer blocks of the block copolymers, wherein the copolymers form a supramolecular structure;
a therapeutic agent that is at least partially encapsulated by the supramolecular structure;
wherein said nanostructure has a cross linking density of 5% to 35%.

### Claim 15 (depends on 14)

The shell-cross linked nanostructure of claim 14 wherein the mole ratio of the pyrazine-containing linking groups to monomers of the poly(acrylic acid) polymer block is selected over a range of 1:100 to 99:100.

### Claim 16 (depends on 1)

The composition of claim 1 and at least one carrier or excipient resulting in a pharmaceutically acceptable composition.

### Claim 17 (depends on 1)

A pharmaceutically acceptable composition comprising at least one carrier or excipient and a composition of claim 1.

### Claim 18 (depends on 1)

A composition according to claim 1, wherein the therapeutic agent is a cytotoxic moiety, a DNA intercalating anthracycline, a chemotherapy agent, an alkylating agent, a DNA intercalator, a microtubule-targeting molecule, a folate antagonist, a nucleoside antimetabolite, an antineoplastic agent, a platinum complex, a Taxol, a Type I photodynamic compound, a Type II photodynamic compound, a leukemia cell binding peptide, doxorubicin or paclitaxel.

### Claim 19 (depends on 1)

A composition according to claim 1, wherein the therapeutic agent is a Taxol, an isolated polypeptide, comprising the amino acid sequence of SEQ ID NO: 1, paclitaxel or doxorubicin.

### Claim 20 (depends on 1)

A composition according to claim 1, wherein the therapeutic agent is a Taxol.
